27321568|t|Efficacy of Intravenous Chlorothiazide for Refractory Acute Decompensated Heart Failure Unresponsive to Adjunct Metolazone
27321568|a|To assess the efficacy of intravenous chlorothiazide in patients with acute decompensated heart failure (ADHF) who were determined to be loop diuretic resistant and refractory to metolazone. Retrospective cohort study with patients serving as their own controls. Large, academic, tertiary care hospital. Forty-five patients with ADHF who had an inadequate response to high-dose loop diuretics and then received at least one dose of oral metolazone 5 mg or greater (metolazone index dose) followed by at least one dose of intravenous chlorothiazide 500 mg (chlorothiazide index dose) if the response to metolazone was considered inadequate, according to the institutional protocol, between February 4, 2013, and February 28, 2015, were included. If multiple doses of metolazone were administered, the last dose given before the chlorothiazide index dose was considered the index dose; the metolazone index dose had to have been administered more than 2 hours before the chlorothiazide index dose. Data for a total of 90 diuretic doses (45 metolazone, 45 chlorothiazide) were included in the analysis. The median dose of loop diuretic in intravenous furosemide equivalents given over the 24- hour period before the metolazone index dose was 400 mg. The average length of stay was 34.7 days, and in-hospital mortality was 35.6% (16/45 patients). The primary end point of a net-negative urine output of 500 ml or greater during the 12 hours after the index dose occurred in 42.2% (19/45 patients) and 35.5% (16/45 patients) for the chlorothiazide and metolazone doses, respectively (p=0.581). The median 12- hour urine output following administration of metolazone was 810 ml (interquartile range [IQR] 866 ml) versus 1075 ml (IQR 940 ml) following administration of chlorothiazide (p=0.363). Compared with metolazone, the chlorothiazide doses did not result in an increase in urine output of at least 500 ml during the 12 hours following the dose relative to the 12 hours before the dose (31.1% vs 22.2%, p=0.754). No significant difference in achievement of net-negative urine output of 500 ml or greater during the 12 hours following the chlorothiazide or metolazone dose was noted (42.2% for chlorothiazide vs 35.5% for metolazone, p=0.581). The addition of intravenous chlorothiazide did not result in improved diuresis in patients with ADHF determined to be refractory to loop diuretic s and adjunctive oral metolazone.
27321568	12	23	Intravenous	T082	UMLS:C0348016
27321568	24	38	Chlorothiazide	T103	UMLS:C0008273
27321568	54	87	Acute Decompensated Heart Failure	T038	UMLS:C1609524
27321568	112	122	Metolazone	T103	UMLS:C0025854
27321568	149	160	intravenous	T082	UMLS:C0348016
27321568	161	175	chlorothiazide	T103	UMLS:C0008273
27321568	193	226	acute decompensated heart failure	T038	UMLS:C1609524
27321568	228	232	ADHF	T038	UMLS:C1609524
27321568	260	273	loop diuretic	T103	UMLS:C0354100
27321568	302	312	metolazone	T103	UMLS:C0025854
27321568	314	340	Retrospective cohort study	T062	UMLS:C2985505
27321568	393	401	academic	T092	UMLS:C1510747
27321568	403	425	tertiary care hospital	T092	UMLS:C0337954
27321568	452	456	ADHF	T038	UMLS:C1609524
27321568	501	515	loop diuretics	T103	UMLS:C0354100
27321568	555	559	oral	T082	UMLS:C0442027
27321568	560	570	metolazone	T103	UMLS:C0025854
27321568	588	598	metolazone	T103	UMLS:C0025854
27321568	644	655	intravenous	T082	UMLS:C0348016
27321568	656	670	chlorothiazide	T103	UMLS:C0008273
27321568	679	693	chlorothiazide	T103	UMLS:C0008273
27321568	725	735	metolazone	T103	UMLS:C0025854
27321568	780	802	institutional protocol	T170	UMLS:C0442711
27321568	889	899	metolazone	T103	UMLS:C0025854
27321568	905	917	administered	T058	UMLS:C0806914
27321568	950	964	chlorothiazide	T103	UMLS:C0008273
27321568	1011	1021	metolazone	T103	UMLS:C0025854
27321568	1050	1062	administered	T058	UMLS:C0806914
27321568	1092	1106	chlorothiazide	T103	UMLS:C0008273
27321568	1142	1150	diuretic	T103	UMLS:C0354100
27321568	1161	1171	metolazone	T103	UMLS:C0025854
27321568	1176	1190	chlorothiazide	T103	UMLS:C0008273
27321568	1213	1221	analysis	T062	UMLS:C0936012
27321568	1242	1255	loop diuretic	T103	UMLS:C0354100
27321568	1259	1270	intravenous	T082	UMLS:C0348016
27321568	1271	1281	furosemide	T103	UMLS:C0016860
27321568	1336	1346	metolazone	T103	UMLS:C0025854
27321568	1493	1505	net-negative	T033	UMLS:C0205160
27321568	1506	1518	urine output	T201	UMLS:C0232856
27321568	1651	1665	chlorothiazide	T103	UMLS:C0008273
27321568	1670	1680	metolazone	T103	UMLS:C0025854
27321568	1732	1744	urine output	T201	UMLS:C0232856
27321568	1773	1783	metolazone	T103	UMLS:C0025854
27321568	1886	1900	chlorothiazide	T103	UMLS:C0008273
27321568	1926	1936	metolazone	T103	UMLS:C0025854
27321568	1942	1956	chlorothiazide	T103	UMLS:C0008273
27321568	1996	2008	urine output	T201	UMLS:C0232856
27321568	2179	2191	net-negative	T033	UMLS:C0205160
27321568	2192	2204	urine output	T201	UMLS:C0232856
27321568	2260	2274	chlorothiazide	T103	UMLS:C0008273
27321568	2278	2288	metolazone	T103	UMLS:C0025854
27321568	2315	2329	chlorothiazide	T103	UMLS:C0008273
27321568	2343	2353	metolazone	T103	UMLS:C0025854
27321568	2381	2392	intravenous	T082	UMLS:C0348016
27321568	2393	2407	chlorothiazide	T103	UMLS:C0008273
27321568	2426	2434	improved	T033	UMLS:C0184511
27321568	2435	2443	diuresis	T038	UMLS:C0012797
27321568	2461	2465	ADHF	T038	UMLS:C1609524
27321568	2497	2510	loop diuretic	T103	UMLS:C0354100
27321568	2528	2532	oral	T082	UMLS:C0442027
27321568	2533	2543	metolazone	T103	UMLS:C0025854